NCT06405555View on ClinicalTrials.gov

Midodrine in Heart Failure With Reduced Ejection Fraction With Hypotension

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

August 1, 2024

Primary Completion Date

April 1, 2026

Study Completion Date

July 1, 2026

Conditions
Heart Failure With Reduced Ejection FractionHypotensionLV Dysfunction
Interventions
DRUG

Midodrine Oral Tablet

Exposure to up to 5 days of midodrine (or until hospital discharge) in hospital at escalating doses with the following protocol: 2.5 mg po TID x 1 day, 5.0 mg po TID x 1 day, 7.5 mg po TID x 1 day, 10 mg po TID x 2 days.

All Listed Sponsors
lead

Ottawa Heart Institute Research Corporation

OTHER

NCT06405555 - Midodrine in Heart Failure With Reduced Ejection Fraction With Hypotension | Biotech Hunter | Biotech Hunter